Page 7

12

kAY hueBNer, Ph.D.

JAmeS WILSON, m.D., Ph.D.

13

February 1995

kay huebner, Ph.D. Basic Science Director, kimmel cancer center Professor, microbiology and Immunology thomas Jefferson university

April 1995

James Wilson, m.D., Ph.D. John herr musser Professor of research medicine chair, Gene therapy Program university of Pennsylvania School of medicine

title:

kidney tumor Suppressor Genes

title:

the Prospects for human Gene therapy

kay huebner, Ph.D. is a member of the Kimmel Cancer Institute and Center and Professor in the Department of Microbiology and Immunology of Thomas Jefferson University. She graduated with an A.B. in Liberal Arts/ Philosophy from St. Johns College, Annapolis, “The Great Books” school, and obtained a Ph.D. degree in Microbiology from the University of Pennsylvania (1974). After postdoctoral work in virology and genetics at the Wistar Institute, an affiliate of the University of Pennsylvania, she joined the Faculty of the Wistar Institute. She moved to the Fels Institute for Cancer Research at Temple University School of Medicine in 1987 and to Thomas Jefferson University in 1991.

Dr. James Wilson is a Professor of Medicine (Medical Genetics Division) and the John Herr Musser Chair of the Department of Research Medicine at the University of Pennsylvania. He is also a Professor at The Wistar Institute. Dr. Wilson received his M.D. and Ph.D. from the University of Michigan in 1984, focusing his research on the study of inborn errors of purine metabolism. Following residency training in Internal Medicine at the Massachusetts General Hospital, he moved to the Whitehead Institute of the Massachusetts Institute of Technology where he pursued postdoctoral training with Richard Mulligan in the area of retroviral vectors and gene therapy. In 1988, he joined the faculty at the University of Michigan where he began his independent career, relocating to the University of Pennsylvania to assume his current positions in 1993. Dr. Wilson’s research accomplishments have been in the area of CF disease pathogenesis, biology of vectors, and early applications of gene therapy in humans. He is the former President of the American Society of Gene Therapy.

Biomedical Series Booklet  
Biomedical Series Booklet  

Biomedical Series Booklet